Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
11/2000
11/09/2000CA2371766A1 Noninvasive genetic immunization, expression products therefrom, and uses thereof
11/09/2000CA2371596A1 Collection of prokaryotic dna for two hybrid systems helicobacter pylori protein-protein interactions and application thereof
11/09/2000CA2371577A1 Forms of prostate specific antigen (psa) specific for benign prostatic hyperplasia (bph) and methods of using such
11/09/2000CA2370821A1 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
11/09/2000CA2369747A1 Mutant human cd80 and compositions for and methods of making and using the same
11/09/2000CA2368748A1 X-ray guided drug delivery
11/09/2000CA2365440A1 Human ion channel proteins
11/09/2000CA2365278A1 Tumour-associated antigen
11/09/2000CA2335966A1 Method for inducing growth and enhancing survival of nervous tissue
11/08/2000EP1049795A1 Mmsc1 - an mmac1 interacting protein
11/08/2000EP1049793A2 Transfecting compositions sensitive to reducing conditions, pharmaceutical compositions containing them, and their applications
11/08/2000EP1049782A1 Mutants of il-16, processes for their production, and their use
11/08/2000EP1049779A2 Lh-receptor gene promoter for tissue-specific gene expression
11/08/2000EP1049776A1 Phagocytosis genes and uses thereof
11/08/2000EP1049774A2 Promoter regions of the mouse and human telomerase rna component genes
11/08/2000EP1049773A1 Inhibition of cytokine production
11/08/2000EP1049772A1 Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth
11/08/2000EP1049769A2 Mutant herpes simplex viruses and uses thereof
11/08/2000EP1049714A1 Secreted proteins and polynucleotides encoding them
11/08/2000EP1049708A1 Meth1 and meth2 polynucleotides and polypeptides
11/08/2000EP1049491A1 Gene therapy of tumors using non-viral delivery system
11/08/2000EP1049488A1 METHOD OF AND COMPOSITIONS FOR IMMUNIZATION WITH THE $i(PSEUDOMONAS) V ANTIGEN
11/08/2000EP1049487A2 Method for treating acute intermittent porphyria (aip) and other porphyric diseases
11/08/2000EP1049484A1 Method of using il-11 to enhance cell mediated immunity for treating various viral and parasitic infections and cancer
11/08/2000EP1049483A1 Method for treating inflammatory diseases using heat shock proteins
11/08/2000EP0789564A4 Polynucleotide compositions
11/08/2000EP0687180B1 Methods for detection and treatment of individuals having abnormal cells expressing hla-a2/tyrosinase peptide antigens
11/08/2000CN1272883A Adipocyte-specific protein homologs
11/08/2000CN1272538A Quick high-effective separation and purification method of virus related to rocombinant adenovirus and its application
11/07/2000US6143878 Sox-9 gene and protein and use in the regeneration of bone or cartilage
11/07/2000US6143870 Thrombin receptor homolog
11/07/2000US6143727 Aministering loricrin or k6 keratin expression vector at or directly around the site of skin cancer cell nucleic acid to result inhibition of the cell's proliferation to treat skin cancer
11/07/2000US6143551 Delivery of polypeptide-encoding plasmid DNA into the cytosol of macrophages by attenuated listeria suicide bacteria
11/07/2000US6143530 Circular DNA expression cassettes for in vivo gene transfer
11/07/2000US6143527 Chain reaction cloning using a bridging oligonucleotide and DNA ligase
11/07/2000US6143522 Activating programmed cell death in eukaryotic cells; amplifying theexpression of peptides or oligonucleotides associated with programmed cell death in eukaryotic cells
11/07/2000US6143521 Human bombesin receptor subtype-3sb
11/07/2000US6143501 Inducing artificial three-dimensional tissues using cell interaction systems such that cultures possessing or developing extracellular matrix are linked via membranes, or are in direct contact with or are mixed with each other
11/07/2000US6143290 Tumor regression by adenovirus expression of wild-type p53
11/07/2000US6143276 Methods for delivering bioactive agents to regions of elevated temperatures
11/07/2000US6143211 Process for preparing microparticles through phase inversion phenomena
11/02/2000WO2000065085A1 Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
11/02/2000WO2000065078A1 A herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells
11/02/2000WO2000065077A1 Triple hybrid amplicon vector systems to generate retroviral packaging lines
11/02/2000WO2000065076A2 Synthetic gene for expressing active retroviral protein in eukaryotes
11/02/2000WO2000065067A2 Prostate-specific polynucleotides, polypeptides and their methods of use
11/02/2000WO2000065063A2 Nucleic acid vaccines against rickettsial diseases and methods of use
11/02/2000WO2000065060A2 Dna sequence and recombinant production of a graminae allergen
11/02/2000WO2000065058A1 Method for down-regulating il5 activity
11/02/2000WO2000065056A2 NUCLEIC ACIDS ENCODING A MutT DOMAIN-CONTAINING POLYPEPTIDE
11/02/2000WO2000065054A2 Human membrane-associated proteins
11/02/2000WO2000065052A1 Bridge-1, a transcription factor
11/02/2000WO2000065043A1 Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension
11/02/2000WO2000065042A1 P element derived vector and methods for its use
11/02/2000WO2000065038A2 Methods, compositions, and cells for encapsidating recombinant vectors in aav particles
11/02/2000WO2000065034A2 Pseudotyped retroviral vector for gene therapy of cancer
11/02/2000WO2000065030A2 Microencapsulated genetically engineered e. coli dh 5 cells for the removal of undesired electrolytes and/or metabolites
11/02/2000WO2000065028A2 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
11/02/2000WO2000064933A1 Transcriptional activation inhibitory protein
11/02/2000WO2000064932A1 Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
11/02/2000WO2000064930A2 Tribonectins
11/02/2000WO2000064929A1 Membrane disruptive peptides covalently oligomerized
11/02/2000WO2000064864A1 N-protected amines and their use as prodrugs
11/02/2000WO2000064488A2 Somatic transgene immunization and related methods
11/02/2000WO2000064468A2 Therapeutic compositions and methods for enhancing angiogenesis
11/02/2000WO2000064465A1 Death domain containing receptors
11/02/2000WO2000064400A2 Methods for treating congestive heart failure
11/02/2000WO2000064377A1 Prosthetic grafts
11/02/2000WO2000043514A3 Human acid sensing ion channel and uses thereof
11/02/2000WO2000041516A3 Reagents and methods useful for detecting diseases of the breast
11/02/2000WO2000041508A3 Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines
11/02/2000WO2000040723A3 Methods and products for delivering nucleic acids
11/02/2000WO2000040714A3 Therapeutic phosphodiesterase inhibitors
11/02/2000WO2000040699A3 Astrocytes, their preparation and uses thereof
11/02/2000WO2000040272A3 P450 / acetaminophen gdept for cancer treatment
11/02/2000WO2000040271A3 P450 / acetaminophen gdept for cancer treatment
11/02/2000WO2000039279A3 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
11/02/2000WO2000039136A3 Human brainiac-5
11/02/2000WO2000037640A9 Compositions and methods for the treatment of tumor
11/02/2000WO2000029024A9 Formulation of adenovirus for gene therapy
11/02/2000WO2000028061A9 Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
11/02/2000WO2000024876A3 Spumavirus isolated from humans
11/02/2000WO2000004926A3 Conjugates for treating inflammatory disorders and associated tissue damage
11/02/2000EP1048727A1 Gene encoding novel transmembrane protein
11/02/2000EP1048725A1 Process for production of mammalian cell lines, produced cell lines and their uses
11/02/2000EP1048724A1 Human myoblast cell lines and their uses
11/02/2000EP1047938A2 Identification of substances that modify cellular secretory function
11/02/2000EP1047792A1 A method for depopulating of vertebrate testis and for generation of transgenic species
11/02/2000EP1047786A2 Nucleic acid corresponding to mutation associated with cholestasis syndromes
11/02/2000EP1047784A2 Neissera meningitidis antigens
11/02/2000EP1047782A1 Interleukin-1 receptor antagonist beta (il-1ra beta)
11/02/2000EP1047779A2 Methods and compositions to alter tissue susceptibility to immune injury, to programmed cell death, and to clearance by the reticuloendothelial system
11/02/2000EP1047774A1 Methods and compositions for gene delivery
11/02/2000EP1047712A1 Fatty acid synthase mrna binding protein
11/02/2000EP1047448A1 Dna vaccines against tick-borne flaviviruses
11/02/2000EP1047443A1 Methods and compositions for enhancing cognitive function using morphogenic proteins
11/02/2000EP1047441A1 Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
11/02/2000DE19919550A1 Verfahren zur Erzeugung von Organismen mit erhöhter Sterolglykosid-Produktion und Verwendung der Sterolglykoside A process for producing organisms with increased Sterolglykosid production and use of Sterolglykoside
11/02/2000CA2650236A1 Porcine reproductive and respiratory syndrome vaccine, based on isolate ja-142
11/02/2000CA2371241A1 Tgf-.alpha. polypeptides, functional fragments and methods of use therefor
1 ... 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 ... 870